|Articles|March 1, 2020
- BioPharm International-03-01-2020
- Volume 33
- Issue 3
BioPharm International, March 2020 Issue (PDF)
Click the title above to open the BioPharm International March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Improving Upstream Predictabilityalmost 6 years ago
The Future of Raw Material Sources for mAbsalmost 6 years ago
Building Data Quality in Generates Quality Data Outalmost 6 years ago
Flexible Facilities for Viral Vector Manufacturingalmost 6 years ago
Stability Testing: The Crucial Development Stepalmost 6 years ago
Navigating GMPs for Gene Therapiesalmost 6 years ago
The Costs of Commercializing CRISPRalmost 6 years ago
Seeking Early Answers to Formulation Questionsalmost 6 years ago
Drug Production Draws Multiple Contendersalmost 6 years ago
Coronavirus Response: Reaction or New Reality?Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
3
Developing Next-Gen Cell Lines Using Targeted Integration
4
FAQ: Shifts in FDA Regulations and Strategies in 2025
5
